Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest

Simply Wall St.03-19

Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620329007?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-19 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620329007","market":"nz","top_or_hot":-1,"title":"Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest","media":"Simply Wall St.","content":"<div>\n<p>Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-after-accelerated-skyway-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-after-accelerated-skyway-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-after-accelerated-skyway-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRE","symbol_name":"SPYRE THERAPEUTICS INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-after-accelerated-skyway-t","article_id":"2620329007","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-after-accelerated-skyway-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620329007","pubTimestamp":1773886073,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third quarter of 2026.\nSee our latest analysis for Spyre Therapeutics.\nAt a share price of $43.06, Spyre’s momentum has been strong, with a 30 day share price return of 17.55% and a 90 day gain of 28.65%. The 1 year total shareholder return of 134.02% and 3 year total shareholder return above 4x...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRE":"SPYRE THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"SKYWAY试验时间表加快和投资者兴趣上升后Spyre Therapeutics(SYRE)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":1.5},"content_text":"Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third quarter of 2026. See our latest analysis for Spyre Therapeutics. At a share price of $43.06, Spyre’s momentum has been strong, with a 30 day share price return of 17.55% and a 90 day gain of 28.65%. The 1 year total shareholder return of 134.02% and 3 year total shareholder return above 4x suggest the recent clinical milestones and accelerated SKYWAY timelines have been met with rising optimism, despite some short term volatility such as the 2.02% 1 day decline. If this kind of biotech catalyst appeals to you, it could be a good moment to broaden your watchlist and check out 35 healthcare AI stocks With SYRE up strongly over the past year and trading at a discount to the average analyst price target, the key question is whether current optimism leaves more room for potential gains or whether the market is already pricing in future growth. AdvertisementPreferred Price-to-Book of 6x: Is It Justified? With Spyre Therapeutics last closing at $43.06, the stock trades on a P/B of 6x, which is below a peer group average of 8.9x but higher than the broader US biotech industry average of 2.6x. P/B compares a company’s market value to its book value. For a clinical stage biotech, it is often a proxy for how the market values its cash, pipeline assets and intellectual property relative to the balance sheet. In Spyre’s case, a 6x P/B suggests investors are assigning a sizable premium over book value, even though the company reported a net loss of $126.542 million and currently generates no revenue. Compared with peers on 8.9x P/B, Spyre trades at a discount that may indicate the market is more cautious on its pipeline or funding mix than on some direct comparables. However, against the wider US biotech industry average of 2.6x, Spyre’s 6x P/B stands out as materially higher, signaling that investors are currently paying more per dollar of book value than is typical across the sector. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 6x (ABOUT RIGHT) However, the story can change quickly if key Phase 2 readouts disappoint or if the company’s clinical progress requires more capital, given the current net loss of $126.542 million. Find out about the key risks to this Spyre Therapeutics narrative. Next Steps Given the mix of optimism and clear risks around Spyre, it makes sense to look at the details yourself and decide where you stand. To round out your view before acting, take a close look at the 4 important warning signs Looking for more investment ideas? If Spyre has grabbed your attention, do not stop here. Use this momentum to line up a few more high conviction ideas that really earn a place on your watchlist.  Target value opportunities that balance quality with attractive pricing by scanning 49 high quality undervalued stocks and see which names stand out for you. Prioritise stability and capital strength by reviewing the solid balance sheet and fundamentals stocks screener (40 results) so you are not relying on just one story to manage risk. Get ahead of the crowd by searching the screener containing 26 high quality undiscovered gems and make sure you spot potential candidates before they become widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620329007","isCrawlerRequest":true}